How does the risk of hepatocellular carcinoma change over time in patients with a hepatitis C cure? Authors' replyALIMENTARY PHARMACOLOGY & THERAPEUTICSIF6.72024-01-100OAAI
Hepatocellular carcinoma risk decreases as time accrues following hepatitis C virus eradicationALIMENTARY PHARMACOLOGY & THERAPEUTICSIF6.72023-11-1311PRE
Combining FIB-4 and Liver Stiffness Into the FIB-5, a Single Model that Accurately Predicts Complications of Portal HypertensionAMERICAN JOURNAL OF GASTROENTEROLOGYIF7.62022-07-153OA
Risk factors for adverse outcomes in emergency versus nonemergency open umbilical hernia repair and opportunities for elective repair in a national cohort of patients with cirrhosisSURGERYIF2.72022-07-0111PRE
Comparison of Moderna versus Pfizer-BioNTech COVID-19 vaccine outcomes: A target trial emulation study in the US Veterans Affairs healthcare systemECLINICALMEDICINEIF102022-03-0128OAAI
Associations Between Alcohol Use and Liver-Related Outcomes in a Large National Cohort of Patients With CirrhosisHEPATOLOGY COMMUNICATIONSIF4.62021-10-0329OAAI
Reduced Incidence of Hepatic Encephalopathy and Higher Odds of Resolution Associated With Eradication of HCV InfectionCLINICAL GASTROENTEROLOGY AND HEPATOLOGYIF122020-05-0118OAAI
Alcohol Use and Long-Term Outcomes Among U.S. Veterans Who Received Direct-Acting Antivirals for Hepatitis C TreatmentHEPATOLOGY COMMUNICATIONSIF4.62020-01-0214OAAI
Hepatitis C eradication with direct-acting anti-virals reduces the risk of variceal bleedingALIMENTARY PHARMACOLOGY & THERAPEUTICSIF6.72019-11-2726OAAI
Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 ScoresGASTROENTEROLOGYIF25.12019-11-01275OAAI
Incidence and Risk Factors of Postoperative Mortality and Morbidity After Elective Versus Emergent Abdominal Surgery in a National Sample of 8193 Patients With CirrhosisANNALS OF SURGERYIF6.42019-10-2532PREAI
Eradication of Hepatitis C Virus Is Associated With Reduction in Hematologic Malignancies: Major Differences Between Interferon and Direct-Acting AntiviralsHEPATOLOGY COMMUNICATIONSIF4.62019-06-1114OAAI
Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis CJOURNAL OF HEPATOLOGYIF332018-11-01120OAAI
End-of-Life Care for Patients With Advanced Kidney Disease in the US Veterans Affairs Health Care System, 2000-2011AMERICAN JOURNAL OF KIDNEY DISEASESIF8.22018-07-0136OAAI
HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinomaJOURNAL OF HEPATOLOGYIF332018-01-01394OAAI
Reply to: Direct-acting antiviral therapy in patients with hepatocellular cancer: The timing of treatment is everything'' and More extended indication of DAA therapy in patients with HCC, affordability, and further statistical considerations''JOURNAL OF HEPATOLOGYIF332018-01-011OAAI
Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinomaJOURNAL OF HEPATOLOGYIF332017-07-01121OAAI
Improvement in Glycemic Control of Type 2 Diabetes After Successful Treatment of Hepatitis C VirusDIABETES CAREIF16.62017-06-28127PREAI
The Association Between Race/Ethnicity and the Effectiveness of Direct Antiviral Agents for Hepatitis C Virus InfectionHEPATOLOGYIF15.82016-12-2465OAAI
Alcohol use and hepatitis C virus treatment outcomes among patients receiving direct antiviral agentsDRUG AND ALCOHOL DEPENDENCEIF3.62016-12-0162OAAI
个人简介
教育背景
工作经历
荣誉奖项
未登录.png){kind=icon}
未登录个人简介教育背景工作经历荣誉奖项
研究方向